Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial

Journal of Palliative Medicine

Volumn 16, Issue 8, 2013, Pages 958-965

  Irwin, Scott A ^a,b   Iglewicz, Alana ^a,b,c   Nelesen, Richard A ^a   Lo, Jessica Y ^a   Carr, Connie H ^a   Romero, Sheilani D ^a   Lloyd, Linda S ^a  

^a Institute for Palliative Medicine at San Diego Hospice   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOSPICE CARE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SITTING; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; HOSPICE CARE; HUMANS; KETAMINE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880852239     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0617     Document Type: Article

References (69)

1. Ferris FD, Balfour HM, Bowen K, Farley J, Hardwick M, Lamontagne C, Lundy M, Syme A, West P: A Model to Guide Hospice Palliative Care. Ottawa, ON: Canadian Hospice Palliative Care Association, 2002.
2. Wilson KG, Chochinov HM, de Faye BJ, Breitbart W: Diagnosis and Management of Depression in Palliative Care. In: Chochinov HM, Breitbart W (eds): Handbook of Psychiatry in Palliative Medicine. New York: Oxford University Press, 2000, pp. 25-50.
3. NIH: National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr 2004;2004:9-16.
4. Wilson KG, Chochinov HM, Skirko MG, Allard P, Chary S, Gagnon PR, Macmillan K, De Luca M, O'Shea F, Kuhl D, Fainsinger RL, Clinch JJ: Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007;33:118-129.
5. McDaniel JS, Brown FW, Cole SA: Assessment of depression and grief reactions in the medically ill. In: Stoudemire A, Fogel BS, Greenberg DB (eds): Psychiatric Care of the Medical Patient. New York: Oxford University Press, 2000, pp. 149-164.
6. King DA, Heisel MJ, Lyness JM: Assessment and psychological treatment of depression in older adults with terminal or life threatening illness. Clin Psychol Sci Pract 2005:339-353.
7. Spiegel D, Bloom JR: Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983;45: 333-339.
8. Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R: Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000;284:2907-2911.
9. Conwell Y, Duberstein PR, Caine ED: Risk factors for suicide in later life. Biol Psychiatry 2002;52:193-204.
10. Alexopoulos GS, Bruce ML, Hull J, Sirey JA, Kakuma T: Clinical determinants of suicidal ideation and behavior in geriatric depression. Arch Gen Psychiatry 1999;56:1048-1053.
11. Waern M, Rubenowitz E, Wilhelmson K: Predictors of suicide in the old elderly. Gerontology 2003;49:328-334.
12. Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry 2003;160: 1-60.
13. Stahl SM: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York: Cambridge University Press, 2008, p. 1117.
14. Irwin SA, Ferris FD: The opportunity for psychiatry in palliative care. Can J Psychiatry 2008;53:713-724.
15. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: Implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
16. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR D report. Am J Psychiatry 2007;164:739-752.
17. National Hospice and Palliative Care Organization: Facts and Figures: Hospice Care in America. Alexandria, VA: NHPCO, 2011.
18. Krystal JH: Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 2007;137:215-216.
19. Kudoh A, Takahira Y, Katagai H, Takazawa T: Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002;95:114-118.
20. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006;63:856-864.
21. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47: 351-354.
22. Correll GE, Futter GE: Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006;7:92-95.
23. Liebrenz M, Borgeat A, Leisinger R, Stohler R: Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007;137:234-236.
24. Liebrenz M, Stohler R, Borgeat A: Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2007:1-4.
25. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeateddose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145.
26. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA, Jr.: Family history of alcohol dependence and initial antidepressant response to an N-methyl-Daspartate antagonist. Biol Psychiatry 2009;65:181-184.
27. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA, Jr.: Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605-1611.
28. Price RB, Nock MK, Charney DS, Mathew SJ: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66:522-526.
29. Larkin GL, Beautrais AL: A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14:1127-1131.
30. Zarate CA, Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA: Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 2012;71:939-946.
31. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA, Jr.: Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, doubleblind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526-1533.
32. Irwin SA, Iglewicz A: Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 2010;13:903-908.
33. Thangathurai D, Roby J, Roffey P: Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med 2010;13:235.
34. Stefanczyk-Sapieha L, Oneschuk D, Demas M: Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008;11:1268-1271.
35. Mercadante S: Ketamine in cancer pain: An update. Palliat Med 1996;10:225-230.
36. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S: Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005;30:485-491.
37. Mercadante S, Arcuri E, Tirelli W, Casuccio A: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-252.
38. Mercadante S, Villari P, Ferrera P: Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003;25:302-305.
39. Lauretti GR, Gomes JM, Reis MP, Pereira NL: Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 1999;11:663-668.
40. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL: Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90:1528-1533.
41. Lossignol DA, Obiols-Portis M, Body JJ: Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005;13:188-193.
42. Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B: "Burst" ketamine for refractory cancer pain: An open-label audit of 39 patients. J Pain Symptom Manage 2001;22:834-842.
43. Meller ST: Ketamine: Relief from chronic pain through actions at the NMDA receptor? Pain 1996;68:435-436.
44. Maeng S, Zarate CA, Jr., Du J, Schloesser RJ, McCammon J, Chen G, Manji HK: Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-352.
45. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-964.
46. Murrough JW: Ketamine as a novel antidepressant: From synapse to behavior. Clin Pharmacol Ther 2012;91:303-309.
47. Hijazi Y, Boulieu R: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;30:853-858.
48. Hijazi Y, Boulieu R: Protein binding of ketamine and its active metabolites to human serum. Eur J Clin Pharmacol 2002;58:37-40.
49. Clements JA, Nimmo WS, Grant IS: Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982;71:539-542.
50. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006, pp. xxiii, 2021.
51. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC, Firestone L, Lavin PT, Mermelstein F: Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. Pain 2004;108:17-27.
52. Kannan TR, Saxena A, Bhatnagar S, Barry A: Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002;23:60-65.
53. Subramaniam K, Subramaniam B, Steinbrook RA: Ketamine as adjuvant analgesic to opioids: A quantitative and qualitative systematic review. Anesth Analg 2004;99:482-495.
54. Fitzgibbon EJ, Hall P, Schroder C, Seely J, Viola R: Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: A strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002;23:165-170.
55. Fine PG: Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999;17:296-300.
56. Clark JL, Kalan GE: Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage 1995;10:310-314.
57. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
58. Lloyd-Williams M, Friedman T, Rudd N: An analysis of the validity of the Hospital Anxiety and Depression scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manage 2001;22:990-996.
59. Folstein MF, Folstein SE, McHugh PR, Fanjiang G: Mini-Mental State Examination User's Guide. Odessa, FL: Psychological Assessment Resources, 2001.
60. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale: An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-2007.
61. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33; quiz 34-57.
62. Cohen SR, Mount BM, Strobel MG, Bui F: The McGill Quality of Life Questionnaire, a measure of quality of life appropriate for people with advanced disease: A preliminary study of validity and acceptability. Palliat Med 1995;9:207-219.
63. Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K: Validity of the McGill Quality of Life Questionnaire in the palliative care setting: A multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med 1997;11:3-20.
64. Bruley DK: Beyond reliability and validity: Analysis of selected quality-of-life instruments for use in palliative care. J Palliat Med 1999;2:299-309.
65. Ludbrook J: On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin Exp Pharmacol Physiol 1991;18:379-392.
66. aan Het Rot M, Zarate CA, Jr., Charney DS, Mathew SJ: Ketamine for depression: Where do we go from here? Biol Psychiatry 2012;72:537-547.
67. Kurul S, Saip P, Aydin T: Totally implantable venous-access ports: Local problems and extravasation injury. Lancet Oncol 2002;3:684-692.
68. Monreal M, Davant E: Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001; 106:69-72.
69. Sasson M, Shvartzman P: Hypodermoclysis: An alternative infusion technique. Am Fam Physician 2001;64:1575-1578.